Publications by authors named "Shanlan Guo"
Article Synopsis
- The study focused on creating a new drug, MMC-ATS-@PLGA, designed to reduce scar tissue growth after glaucoma filtering surgery while maintaining stable intraocular pressure levels.
- It involved testing the drug's properties, safety, and therapeutic effects through lab and clinical studies, yielding positive results in preventing scar proliferation in rabbit models.
- The findings suggest that MMC-ATS-@PLGA shows promise as a safe and effective treatment option for managing post-surgery inflammation without adversely affecting eye pressure, warranting further clinical investigation.
Sodium glucose cotransporter inhibitor (SGLTi) drugs have been widely used in clinical practice. In addition to their benefits in hyperglycemia, heart failure (HF), and kidney disease, their effects on obesity, metabolic dysfunction-associated steatotic liver disease (MASLD, formerly named nonalcoholic fatty liver disease [NAFLD]), polycystic ovarian syndrome (PCOS), abnormal lipid metabolism, hyperuricemia, obstructive sleep apnea syndrome (OSAS), anemia, and syndrome of inappropriate antidiuresis (SIAD, formerly named syndrome of inappropriate antidiuretic hormone [SIADH]) have been explored. In this review, we searched the data of clinical randomized controlled trials (RCTs) and meta-analyses of SGLTis in patients with diabetes from the PubMed library between January 1, 2020, and February 1, 2024.
View Article and Find Full Text PDF